Greenfield, IN, United States of America

Richard Duane Johnston

This inventor holds 14 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Eli Lilly and Company, Dow Agrosciences LLC, Other. Active years: 1999-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Duane Johnston. Retrieved from https://idiyas.com/inventor/richard-duane-johnston

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 4)

% Patents Active = 71.4

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 6.5

ph-index = 2

Forward Citations = 80(Granted Patents)

Company Filing History:

12 out of 4,509

Eli Lilly and Company

1 out of 834,453

Other

patents

Years Active: 1999-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12723053 - KRas inhibitors (2026-09-01),

2. 12503442 - Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators (2025-12-23),

3. 12479829 - 2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compounds (2025-11-25),

4. 12351591 - KRas inhibitors (2025-07-08),

5. 11999722 - Disubstituted pyrazole compounds (2024-06-04),

6. 11180503 - [1,2,4]Triazolo[4,3-A]pyrazin-6(5H)-one derivatives (2021-11-23),

7. 11124500 - Disubstituted pyrazole compounds (2021-09-21),

8. 9637495 - CGRP receptor antagonists (2017-05-02),

9. 7612067 - Imidazopyridazine compounds (2009-11-03),

10. 7544812 - Peroxisome proliferator activated receptor agonists (2009-06-09),

11. 7304062 - Peroxisome proliferator activated receptor alpha agonists (2007-12-04),

12. 7205321 - Peroxisome proliferator activated receptor alpha agonists (2007-04-17),

13. 6005108 - N-([1,2,4]triazoloazinyl)benzenesulfonamide and pyridinesulfonamide (1999-12-21),

14. 5858924 - N-(�1, 2, 4! triazoloazinyl) benzenesulfonamide and pyridinesulfonamide (1999-01-12),

Title: Richard Duane Johnston: Innovator in Pharmaceutical Developments

Introduction

Richard Duane Johnston is an accomplished inventor based in Greenfield, Indiana, with a remarkable portfolio of ten patents to his name. His work primarily focuses on pharmaceutical compounds that have significant applications in treating various metabolic conditions, showcasing his contributions to the field of medical innovations.

Latest Patents

Among his notable inventions, Richard's most recent patents include:

1. **Disubstituted Pyrazole Compounds** - This invention presents a compound of Formula I, or a pharmaceutically acceptable salt thereof, aimed at treating metabolic conditions such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

2. **Triazolo[4,3-A]pyrazin-6(5H)-One Derivatives** - This patent provides a compound of Formula (I), which can serve as a human PDE1 inhibitor. The specific configurations of the compound offer versatility in its application, particularly concerning its components like X, Y, R, and A.

Career Highlights

Richard has made significant strides in his career, having worked with esteemed companies such as Eli Lilly and Company and Dow Agrosciences LLC. His experience in these organizations has undoubtedly influenced his innovative approach and commitment to developing effective pharmaceutical solutions.

Collaborations

Throughout his journey, Richard has collaborated with several talented individuals, including Richard Craig Thompson and Nathan Bryan Mantlo. These partnerships have enriched his research and development endeavors, contributing to the successful outcomes of his patented inventions.

Conclusion

In summary, Richard Duane Johnston stands out as a prominent figure in the realm of pharmaceutical innovation. With a solid track record of patents addressing critical health issues, his work continues to impact the medical field positively, paving the way for advancements in treatments for various metabolic conditions.

Profile summary based on public USPTO records.